C4 Therapeutics (CCCC) Total Liabilities (2019 - 2026)

C4 Therapeutics has reported Total Liabilities for 8 years, with the latest figure at $94.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 23.93% year-over-year to $94.6 million; the trailing twelve-month figure through Mar 2026 stood at $94.6 million (down 23.93% YoY), and the FY2025 full-year result was $102.5 million, down 23.3% from the prior year.
• Total Liabilities for Q1 2026 stood at $94.6 million, down from $102.5 million in the prior quarter.
• The five-year high for Total Liabilities was $151.0 million in Q1 2022, with the low at $94.6 million in Q1 2026.
• Average Total Liabilities over 5 years is $129.5 million, with a median of $133.6 million recorded in 2023.
• Year-over-year, Total Liabilities soared 36.86% in 2022 and declined 23.93% in 2026.
• Tracing CCCC's Total Liabilities over 5 years: stood at $141.6 million in 2022, then decreased by 7.96% to $130.3 million in 2023, then climbed by 2.52% to $133.6 million in 2024, then decreased by 23.3% to $102.5 million in 2025, then declined by 7.68% to $94.6 million in 2026.
• The last three Total Liabilities figures came in at $94.6 million (Q1 2026), $102.5 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.

Peer Comparison